Charlottes fountain of youth


Semaglutide is a GLP-1 that communicates with the brain to suppress appetite and trigger feelings of fullness. When incorporated into a holistic approach involving a balanced diet and regular exercise, Semaglutide can lead to substantial weight loss. 

Moreover, it can reduce the risk of conditions such as cancer, diabetes, and heart disease in individuals dealing with obesity or excess weight.



Tirzepatide, functioning as a GIP and GLP-1 receptor agonist, delivers remarkable improvements in glycemic control for type 2 diabetics and substantial weight reduction. The FDA granted approval to Tirzepatide in May 2022, marking a significant milestone. Additionally, it can be employed off-label for addressing obesity concerns.

Send Us A Message

Please enable JavaScript in your browser to complete this form.

Get In Touch


3120 Latrobe Drive Suite 140
Charlotte, NC 28211



Follow Us